Paul Tudor Jones's AGIO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 61,345 shares of Agios Pharmaceuticals, Inc. (AGIO) worth $1.67 M, representing 0.00% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in AGIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 83,815 shares. Largest reduction occurred in Q2 2022, reducing 56,607 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Agios Pharmaceuticals (AGIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Agios Pharmaceuticals (AGIO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +61,345 | New Buy | 61,345 | $27.22 |
| Q1 2025 | -28,553 | Sold Out | 0 | $0.00 |
| Q4 2024 | +28,553 | New Buy | 28,553 | $32.86 |
| Q2 2024 | -35,734 | Sold Out | 0 | $0.00 |
| Q1 2024 | +7,836 | Add 28.09% | 35,734 | $29.24 |
| Q4 2023 | +27,898 | New Buy | 27,898 | $22.27 |
| Q2 2023 | -14,755 | Sold Out | 0 | $0.00 |
| Q1 2023 | -10,810 | Reduce 42.28% | 14,755 | $0.02 |
| Q4 2022 | +3,221 | Add 14.42% | 25,565 | $0.03 |
| Q3 2022 | -384 | Reduce 1.69% | 22,344 | $28.28 |
| Q2 2022 | -56,607 | Reduce 71.35% | 22,728 | $22.18 |
| Q1 2022 | -4,480 | Reduce 5.35% | 79,335 | $29.10 |
| Q4 2021 | +83,815 | New Buy | 83,815 | $32.87 |
| Q2 2021 | -7,690 | Sold Out | 0 | $0.00 |
| Q1 2021 | -17,277 | Reduce 69.20% | 7,690 | $51.63 |
| Q4 2020 | -31,371 | Reduce 55.68% | 24,967 | $43.34 |
| Q3 2020 | +39,493 | Add 234.45% | 56,338 | $35.00 |
| Q2 2020 | +16,845 | New Buy | 16,845 | $53.49 |
| Q4 2019 | -13,815 | Sold Out | 0 | $0.00 |
| Q3 2019 | +4,654 | Add 50.80% | 13,815 | $32.43 |
| Q2 2019 | +9,161 | New Buy | 9,161 | $49.89 |
| Q3 2015 | -1,900 | Sold Out | 0 | $0.00 |
| Q2 2015 | +1,900 | New Buy | 1,900 | $111.05 |
| Q1 2015 | -2,061 | Sold Out | 0 | $0.00 |
| Q4 2014 | +2,061 | New Buy | 2,061 | $112.08 |
Paul Tudor Jones's Agios Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Agios Pharmaceuticals, Inc. (AGIO) in Q4 2014, acquiring 2,061 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Agios Pharmaceuticals, Inc. (AGIO) for 25 quarters since Q4 2014.
Paul Tudor Jones's largest addition to Agios Pharmaceuticals, Inc. (AGIO) was in Q4 2021, adding 83,815 shares worth $2.76 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 61,345 shares of Agios Pharmaceuticals, Inc. (AGIO), valued at approximately $1.67 M.
As of the Q4 2025 filing, Agios Pharmaceuticals, Inc. (AGIO) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Agios Pharmaceuticals, Inc. (AGIO) was 83,815 shares, as reported at the end of Q4 2021.